Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. (IDRA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
idra · stock forecast · 9 analysts (3M) · FMP · updated Aug 27, 2025
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.42
Short-Term Price Prediction
Short-term predictions are paused during the ±3-day earnings window to avoid unreliable signals.
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IDRA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-03-19 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2021-03-19 | JMP Securities | Downgrade ↓ | Outperform→Perform |
| 2021-03-19 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2021-03-19 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2018-09-24 | Barclays | Maintains | Overweight→Overweight |
| 2018-07-16 | Wedbush | Maintains | Outperform→Outperform |
| 2018-06-13 | Baird | Maintains | Outperform→Outperform |
| 2018-06-13 | JMP Securities | Maintains | Market Outperform→Outperform |
| 2017-11-09 | H.C. Wainwright | Maintains | Buy→Buy |
| 2017-04-24 | Baird | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Idera Pharmaceuticals, Inc. (IDRA) stock. Of the recent 15 rating actions, 0 were upgrades and 4 were downgrades. 9 analysts currently cover IDRA.
Analyst Recommendation Trends
IDRA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast IDRA EPS of $— for the current fiscal year, based on estimates from 0 analysts. The IDRA revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IDRA stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IDRA price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The IDRA stock price prediction for 2027 estimates an average of $0. The IDRA stock prediction for 2030 projects a range of $0–$0.
Idera Pharmaceuticals, Inc. trades on NASDAQ under the ticker IDRA. The IDRA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.
Frequently asked questions
IDRA forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month IDRA price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.42.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.